BridgeBio Oncology (BBOT) grants COO 758,222 stock options

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics COO and Principal Financial Officer Elmelech Idan received a grant of stock options for 758,222 shares of Common Stock. The options have an exercise price of 7.6600 per share and expire on May 9, 2036. Vesting occurs in 48 substantially equal monthly installments beginning on April 20, 2026, contingent on continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Elmelech Idan

Role COO & Principal Financial Ofcr

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	758,222	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 758,222 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 758,222 options Exercise price: 7.6600 per share Expiration date: May 9, 2036 +3 more

6 metrics

Stock options granted 758,222 options Grant to COO & Principal Financial Officer

Exercise price 7.6600 per share Strike price for granted stock options

Expiration date May 9, 2036 Option term end for this grant

Underlying shares 758,222 shares Common Stock underlying the options

Post-transaction derivative holdings 758,222 options Total options held following transaction

Vesting schedule 1/48 monthly installments Monthly vesting from April 20, 2026

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "7.6600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-05-09T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"footnote: "1/48th of the shares subject to such option vest and become exercisable...""

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Elmelech Idan

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO & Principal Financial Ofcr

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.66	05/10/2026		A		758,222		(1)	05/09/2036	Common Stock	758,222	$0	758,222	D

Explanation of Responses:

1. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 20, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

	/s/ Aaron Chan, Attorney-in-Fact	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BBOT report for Elmelech Idan?

BridgeBio Oncology Therapeutics reported that COO and Principal Financial Officer Elmelech Idan received a grant of stock options for 758,222 shares of Common Stock. This is a compensation-related award, not an open-market trade, and increases his potential future equity exposure.

What are the key terms of Elmelech Idan’s BBOT stock option grant?

The grant covers 758,222 stock options with an exercise price of 7.6600 per share and an expiration date of May 9, 2036. Each option represents the right to buy one share of BridgeBio Oncology Therapeutics Common Stock under specified vesting conditions.

How do the BBOT stock options granted to Elmelech Idan vest?

One forty-eighth of the 758,222 options vests in substantially equal monthly installments on each monthly anniversary of April 20, 2026. Vesting on each date is conditioned on Elmelech Idan’s continuous service to BridgeBio Oncology Therapeutics, making it a long-term incentive structure.

Is the BBOT Form 4 transaction a purchase or a compensation award?

The Form 4 describes a compensation award, coded as a grant or other acquisition of derivative securities. The transaction is a stock option grant to Elmelech Idan, not an open-market purchase or sale, and reflects equity-based compensation rather than immediate cash investment or divestment.

How many BBOT options does Elmelech Idan hold after this grant?

After the reported transaction, Elmelech Idan holds 758,222 stock options directly according to the filing. This total reflects the newly granted options as derivative securities linked to BridgeBio Oncology Therapeutics Common Stock, subject to vesting and exercisability over the defined schedule.